Vorasidenib
ATC L01XM04 · 8 markets · 18 records
AU 5 records · 3 strengths
- 40 mgtabletVORANIGOVORANIGO vorasidenib 10 mg tablet bottle
- 10 mgtabletVORANIGOVORANIGO vorasidenib 10 mg tablet bottle
Records without a stated strength · 1 VORANIGO
US 2 records · 2 strengths
GB 2 records · 2 strengths
CA 2 records · 2 strengths
TW 2 records · 2 strengths
HK 2 records · 1 strengths
Records without a stated strength · 1 VORANIGO
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 VORANIGO
| Strength / form / release | US | GB | CA | AU | TW | HK | EU |
|---|---|---|---|---|---|---|---|
| 40 mg tablet | VORANIGO | VORANIGO | VORANIGO | VORANIGO VORANIGO vorasidenib 10 mg tablet bottle | VORANIGO 瓦拉固膜衣錠40毫克 | ||
| 10 mg tablet | VORANIGO | VORANIGO | VORANIGO | VORANIGO VORANIGO vorasidenib 10 mg tablet bottle | VORANIGO 瓦拉固膜衣錠10毫克 | ||
unknown | VORANIGO | VORANIGO | VORANIGO |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.